23andMe versus a clinical HLA test for celiac disease: what each reads and what a negative means
Short answer
The 23andMe celiac report that FDA authorized43 reads one variant, rs2187668, a stand-in for the DQ2.5 type, and does not report DQ81, 2; FDA says the absence of a variant the report tests does not rule out other variants that may be disease-related10. Clinical HLA typing reports DQ2 and DQ8 at the DQA1 and DQB1 genes3, 4, and a lab’s negative is described as ruling celiac disease out or essentially ruling it out5, 6. Neither kind of test diagnoses celiac disease7, 8, 29.
Part of Celiac genetics and family risk, 15 guides

Key points
- FDA describes the 23andMe celiac report as reading a tag variant (rs2187668) for HLA-DQ2.5, and says it is not indicated for DQ89, 2.
- Quest’s and Labcorp’s clinical panels report DQ2 and DQ8 by allele3, 4.
- Quest says a negative for both DQ2 and DQ8 rules out celiac disease with 99% confidence; FDA says the absence of a variant the 23andMe report tests does not rule out other variants that may be disease-related5, 10.
- A positive from either kind of test is not a diagnosis7, 8.
What each kind of test reads
Clinical HLA typing looks for groups of gene variants called DQ2 and DQ8, on a blood sample or a cheek swab that a health care professional may take11. A consumer report is built differently, as the table shows.
| 23andMe celiac report, as FDA described it | Clinical lab panels | |
|---|---|---|
| Sample and who orders | DNA from a saliva sample12. FDA’s summary calls the service direct-to-consumer and over-the-counter45. FDA describes direct-to-consumer tests as marketed without the involvement of a health care provider13. | A health care professional may take a blood sample or cheek swab11. |
| What it reads | One variant, rs2187668, in the HLA-DQA1 gene, used as a tag for the HLA-DQ2.5 haplotype1, 9. | Quest: HLA-DQ2 (DQA1*05/DQB1*02), HLA-DQ8 (DQA1*03/DQB1*0302), HLA-DQA1* and HLA-DQB1*3. Labcorp: HLA-DQ2 (DQA1*05:01 or 05:05 and DQB1*02:01 or 02:02) and HLA-DQ8 (DQB1*03:02)4. |
| DQ8 | FDA says the report is not indicated for reporting DQ82. | Reported by both labs3, 4. |
| What the report says | Whether the person has a haplotype associated with higher risk; FDA says it does not describe overall risk14. | Labcorp: a positive result is not diagnostic, but it identifies predisposition8. |
We could not open 23andMe’s own support pages, which blocked automated access, so the middle column is the report as FDA’s decision summary describes it, not what a current account shows. Check your own report for the variants it names.
FDA says not all direct-to-consumer genetic test companies test for the same set of variants, so they may give different results for the same condition15. A result from another company’s kit has to be read against the variants that kit lists.
Why one variant is a stand-in, and what it leaves out
FDA says the DQ2.5 molecule is encoded by two alleles, DQA1*05 and DQB1*0216. The 23andMe report does not read those alleles directly: FDA describes rs2187668 as a representative, or tag, SNP for the haplotype9. One 2023 protocol paper says the DQ2.5 and DQ8 alleles can be accurately predicted by two tagging SNPs, rs2187668 and rs7454108 respectively17. FDA describes the 23andMe report as using the first of those and says it is not indicated for DQ89, 2.
That leaves types the report does not cover. FDA calls DQ8 a type associated with celiac disease in a minority of cases2. Coeliac UK names a third type, DQ2.2, as low risk but not no risk18; FDA’s description of the 23andMe report names DQ2.5 as the type it reports on1.
How much of celiac disease each type covers depends on whose figure you read. FDA’s summary says 90% of patients with celiac disease have at least one copy of DQ2.519. Labcorp says HLA-DQ2 is found in more than 90% of celiac cases, HLA-DQ8 in ~ 5%, and half DQ2 in almost all remaining cases20.
FDA also says the report is most relevant for people of European descent14.
What a negative means from each
A negative from a clinical lab
Both US labs describe a negative as ruling celiac disease out, or essentially ruling it out. Quest says a negative for both DQ2 and DQ8 rules it out with 99% confidence5. Labcorp says a negative on its Celiac HLA DQ Association test essentially rules out celiac disease6. NIDDK says that a person without DQ2 or DQ8 is very unlikely to have celiac disease21.
Coeliac UK keeps the hedge: some very rare patients carry none of DQ2.5, DQ8 or DQ2.2, and a negative, though never a guarantee, would be very reassuring22. One US study typed 10,191 people at risk for celiac disease, and celiac disease was identified by a positive EMA antibody test23. DQ2 and DQ8 were absent in 4283 samples, and 0.16% of those were EMA positive (95% CI 0.07 to 0.34)24.
A negative from the consumer report
FDA’s conditions for the 23andMe report say the absence of a variant tested does not rule out the presence of other genetic variants that may be disease-related10. Its risk analysis lists false negatives as a risk: they can delay identifying genetic risk, potentially resulting in an inappropriate exclusion of the disease from clinical diagnosis assessment25. FDA’s consumer page makes the general point that some genetic health risk tests do not report all known variants that might contribute to risk26.
Since the report reads one variant and is not indicated for DQ81, 2, a negative on it speaks to that variant, while the lab panels above also type DQ83, 4.
What a positive means from each
Many people carry these types. FDA’s summary says approximately 25% of the general population in Europe tests positive for DQ2.527. Coeliac UK says the DQ2 and DQ8 haplotypes are found in up to 40% of the general population, against an estimated UK prevalence of celiac disease of 1%28. Quest says 30% of Caucasians carry DQ2 and DQ829. NIDDK says most people with these gene variants do not develop celiac disease30.
Coeliac UK says a positive for DQ2.5, DQ8 or DQ2.2 does not diagnose celiac disease, and calls it not very helpful in the case it describes, since so many in the general population are DQ positive and yet do not have it31. Labcorp says a positive result is not diagnostic but identifies predisposition8.
Clinical typing can separate groups whose rates differ. In the US study above, 28.28% of samples homozygous for DQ2.5, or DQ2.2/DQ2.5, were EMA positive32, against 9.09% of DQ2.5 heterozygous samples33. Those are one study’s figures from an at-risk population.
What neither test does
FDA’s conditions for the 23andMe report say the test does not diagnose any specific health conditions and results should not be used to make medical decisions7. It also says the test is not a substitute for visits to a healthcare provider34.
Clinical HLA typing does not diagnose either8, 29. NIDDK says doctors most often use blood tests and biopsies of the small intestine to diagnose or rule out celiac disease, and that doctors do not recommend starting a gluten-free diet before diagnostic testing because the diet can affect test results35. The abstract of the 2023 American College of Gastroenterology guideline says detecting celiac-specific antibodies in serum is very helpful for initial screening, and that intestinal biopsy is required in most patients to confirm the diagnosis36.
Who receives the result, and what the law covers
FDA’s summary of the 23andMe report notes that US law (GINA) protects against genetic discrimination in health insurance and employment but not in life, disability or long-term care insurance, and that the manufacturer stated it would not share a user’s personal information with an insurance company without explicit consent37.
What labs and clinicians use HLA typing for
Coeliac UK, writing for UK healthcare professionals, says genetic testing is not routinely recommended in the diagnosis pathway but can have an important role in ruling out patients who will not likely need future testing38. It adds that HLA typing the general population is not recommended or currently practised; current practice is to use it in specific at-risk scenarios, primarily to exclude the condition39.
- Labcorp lists its Celiac HLA DQ Association test for individuals on a gluten-free diet at risk for celiac disease, asymptomatic relatives of a patient with celiac disease, or patients with ambiguous antibody or biopsy results40.
- In its scenario of a patient on a gluten-free diet without a diagnosis, Coeliac UK notes that some patients choose a commercial test and look for an explanation of the results41.
Reports are not uniform. Quest names DQ8 as DQA1*03/DQB1*0302 while Labcorp names it DQB1*03:023, 4, and Coeliac UK says the format of reporting is not standardised in the UK42. Whether to have any of these tests is a decision for the person and their clinician, not for this page.
Questions people ask
Does 23andMe test for celiac disease?
FDA lists 23andMe’s genetic health risk test, which includes a celiac report, among direct-to-consumer tests with marketing authorization43, and its decision summary was first issued in April 201744. The celiac report reads one variant tied to HLA-DQ2.5 and does not diagnose celiac disease1, 7. We could not open 23andMe’s own pages, so we cannot say what the report in a current account shows.
Does a negative 23andMe celiac result rule out celiac disease?
FDA’s conditions say the absence of a tested variant does not rule out other disease-related variants10, and the report is not indicated for DQ82. Clinical labs describe their own negative as ruling out, or essentially ruling out, celiac disease5, 6.
More in Celiac genetics and family risk
Celiac genetic testing: what HLA-DQ2 and DQ8 results can and cannot tell youWhat HLA-DQ2 and DQ8 typing checks for, how NIDDK, ACG, ESPGHAN and WGO read a negative or positive result, and where the guidelines place the test.
A positive celiac gene test in your child: what it means and what happens nextWhat a positive HLA (DQ2 or DQ8) result in a child means, why sources say gluten stays in the diet until testing, and what clinicians check next.
Gone gluten-free without testing: what an HLA gene test can settleWhat an HLA-DQ2/DQ8 gene test can and cannot settle if you stopped gluten before celiac testing, and what sources say a gluten challenge involves.
Celiac disease genes beyond HLA: what large genetic studies foundWhat large genetic studies found beyond HLA in celiac disease, how much of the inherited risk those regions explain, and whether clinical tests cover them.
Celiac genetic test results in the US: who can see them, and what the law coversWhat US law covers when a genetic test result exists, such as a celiac HLA result: health insurance, jobs, the gaps, and a test company's policy.
Screening first-degree relatives for celiac disease: who, when and how oftenWhat the ACG, NICE, BSG, ESPGHAN and NIDDK say about testing parents, siblings and children of someone with celiac disease, and how often.
Related guides
HLA-DQ2 and HLA-DQ8 explained: the allele names on a celiac gene reportWhat DQA1, DQB1, DQ2.5, DQ2.2 and DQ8 mean on a celiac gene report, how often each appears in celiac disease, and how common they are overall.
Positive celiac blood test but a normal biopsy: what doctors call potential celiac diseaseWhat celiac guidelines say when antibodies are positive but the biopsy looks normal: potential celiac disease, other causes, and the follow-up described.
Sources
- [1, 2, 7, 9, 10, 12, 14, 16, 19, 25, 27, 34, 37, 44, 45] US Food and Drug Administration, De Novo decision summary DEN160026: 23andMe Genetic Health Risk Test, including celiac disease (issued 2017), checked Nov 17, 2026.
- [3, 5, 29] Quest Diagnostics, Celiac disease: testing helps you know (clinician overview), checked Nov 17, 2026.
- [4, 6, 8, 20, 40] Labcorp, Celiac disease testing services (clinician brochure), checked Nov 17, 2026.
- [11, 21, 30, 35] National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Diagnosis of celiac disease, checked Nov 17, 2026.
- [13, 15, 26, 43] US Food and Drug Administration, Direct-to-consumer tests, checked Nov 17, 2026.
Read on 2026-11-17: the list headed “Lists of Direct-To-Consumer Tests with Marketing Authorization” names “23andMe PGS Genetic Health Risk Test (DEN160026)”, whose indications include a Genetic Health Risk Report for Celiac Disease.
- [17] Methods in Cell Biology (PubMed), A fast, cheap, and easy protocol for celiac disease HLA haplotype typing using buccal swabs (2023), abstract, checked Nov 17, 2026.
- [18, 22, 28, 31, 38, 39, 41, 42] Coeliac UK, Genetics and coeliac disease testing (healthcare professionals), checked Nov 17, 2026.
- [23, 24, 32, 33] Clinical Gastroenterology and Hepatology (PubMed), Stratifying risk for celiac disease in a large at-risk United States population by using HLA alleles (Pietzak et al., 2009), checked Nov 17, 2026.
- [36] American Journal of Gastroenterology (PubMed), American College of Gastroenterology Guidelines Update: Diagnosis and Management of Celiac Disease (2023), abstract, checked Nov 17, 2026.